Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Larry Culp, Thomas Joyce, Alexandre Mérieux


Danaher said this week that President and CEO Lawrence Culp will retire in March 2015, and that he will be succeeded by current Executive VP Thomas Joyce.

After he steps down from his posts, Culp will continue serving Danaher in an advisory role into the first quarter of 2016. Culp has been Danaher's president and CEO for 13 years, the company said. Joyce has served Danaher as executive VP since 2006, and he currently is in charge of the company's diagnostics, life sciences, and water quality platforms. He has worked for the company in various capacities dating back to 1989.

BioMérieux said this week that Alexandre Mérieux has assumed the role of CEO. He was previously a deputy chief executive officer and corporate vice-president of microbiology unit and manufacturing and supply operations at the company.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.